Teva Announces Tentative Approval of Ondansetron Injection USP

Jerusalem, Israel, February 26, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company?s ANDAs for Ondansetron Injection USP, 2 mg/mL, packaged in 4 mg/2 mL single-dose vials and Ondansetron Injection USP, 2 mg/mL, packaged in 40 mg/20 mL multiple-dose vials.

Source: Teva Pharmaceutical Industries